SB 415286
SIGMA/S3567 - ≥98% (HPLC)
Synonym: 3-
CAS Number: 264218-23-7
Empirical Formula (Hill Notation): C16H10N3O5Cl
Molecular Weight: 359.72
MDL Number: MFCD04039789
Linear Formula: C16H10N3O5Cl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | yellow to orange |
| InChI | 1S/C16H10ClN3O5/c17-10-7- |
| InChI key | PQCXVIPXISBFPN-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 100 ![]() |
| SMILES string | Oc1ccc(NC2=C(C(=O)NC2=O)c |
| solubility | DMSO: 5 mg/mL, clear |
| H2O: insoluble | |
| storage temp. | −20°C |
| Application: | SB 415286 was used to treat neuroblastoma cells and study the effect of GSK-3 inhibition on cell proliferation. |
| Biochem/physiol Actions: | Glycogen synthase kinase-3 (GSK-3) inhibitor. |
| Biochem/physiol Actions: | SB 415286 is a small molecule inhibitor of GSK-3 in muscle and fat cells. SB 415286 induces activation of glycogen synthase and regulates the transport glucose. SB 415286 reduces the systemic inflammation induced by endotoxic shock in rat model of acute colitis. It increases the axonal growth and promotes the recovery of injured adult CNS neurons. SB 415289 is implicated in inducing chromosome instability when used as therapeutic agents. |
| Features and Benefits: | This compound is featured on the GSK-3 and PKB/Akt pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Legal Information: | Sold for research purposes under agreement from GlaxoSmithKline. |
| Packaging: | 5, 25 mg in glass bottle |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |

